ImmunityBio, Inc. (IBRX) Income Statement
IBRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIBRX revenue and net income
Where IBRX's revenue goes
2025Each bar shows an amount and its share of revenue. IBRX kept −310.2% of revenue as net income.
IBRX profit margins
IBRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +668.3% | +678.6% | +184.8% | +85.4% |
| Gross profit | +663.2% | +676.9% | +184.4% | +85.3% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IBRX quarterly EPS vs estimates
ImmunityBio beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.08).
IBRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 | $605,000 | $43,000 | $47,000 | $45,000 | $44,000 |
| Cost of revenue | $753,000 | $17.6M | $18.5M | $24.2M | $0 | $9.1M | $9.0M | −$3.1M | $0 | $0 |
| Gross profit | $112.5M | $14.7M | $622,000 | $240,000 | $934,000 | $605,000 | −$9.0M | $3.2M | $45,000 | $44,000 |
| Research & development | $207.9M | $190.1M | $232.4M | $248.1M | $196.0M | $139.5M | $48.9M | $53.4M | $39.8M | $26.5M |
| Sales, general & admin | $150.0M | $168.8M | $122.7M | $102.7M | $135.3M | $27.3M | $18.1M | $35.5M | $57.1M | $96.4M |
| Total operating expenses | $368.6M | $358.9M | $362.9M | $351.5M | $331.2M | $221.5M | $57.9M | $88.9M | $93.6M | $120.9M |
| Operating income | −$256.0M | −$344.2M | −$362.2M | −$351.3M | −$330.3M | −$220.9M | −$66.9M | −$98.4M | −$99.1M | −$124.5M |
| Interest income | $2.7M | $2.4M | $2.0M | $2.7M | $836,000 | $1.2M | $1.6M | $1.9M | $3.6M | $5.2M |
| Interest expense | $112.5M | $131.7M | $86.7M | $47.1M | $14.8M | $9.1M | $5.9M | $433,000 | $618,000 | $66,000 |
| Income before taxes | −$351.6M | −$413.6M | −$583.9M | −$417.3M | −$349.8M | −$226.0M | −$65.9M | −$96.7M | −$96.9M | −$121.4M |
| Income taxes | −$135,000 | $81,000 | −$40,000 | $34,000 | $9,000 | −$1.8M | −$97,000 | −$503,000 | −$493,000 | −$572,000 |
| Net income | −$351.4M | −$413.6M | −$583.2M | −$416.6M | −$346.8M | −$221.9M | −$65.8M | −$96.2M | −$96.4M | −$120.8M |
| EBITDA | −$223.6M | −$264.4M | −$478.7M | −$351.9M | −$320.8M | −$204.2M | −$56.9M | −$86.7M | −$90.7M | −$117.7M |
| EPS (diluted) | −$0.38 | −$0.60 | −$1.16 | −$1.05 | −$0.89 | −$0.89 | −$0.71 | −$1.22 | −$1.20 | −$1.47 |
| Gross margin | 99.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −20,858.1% | 6,717.0% | 100.0% | 100.0% |
| Operating margin | −226.0% | −2,334.2% | −58,239.5% | −146,374.2% | −35,361.9% | −36,509.1% | −155,597.7% | −209,338.3% | −220,266.7% | −282,954.5% |
| Net margin | −310.2% | −2,804.8% | −93,761.4% | −173,569.6% | −37,129.6% | −36,669.6% | −152,997.7% | −204,736.2% | −214,273.3% | −274,565.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.2M | $44.2M | $38.3M | $32.1M | $26.4M | $16.5M | $7.6M | $6.1M | $1.0M | $40,000 | $139,000 | $82,000 |
| Cost of revenue | $298,000 | $238,000 | $4.2M | $4.1M | $136,000 | $58,000 | $4.1M | $152,000 | $4.4M | $4.6M | $4.6M | $4.6M |
| Gross profit | $50.9M | $44.0M | $34.0M | $27.9M | $26.3M | $16.5M | $7.6M | $6.1M | $1.0M | $40,000 | $139,000 | $82,000 |
| Research & development | $57.7M | $64.8M | $60.8M | $50.7M | $55.2M | $48.2M | $35.2M | $50.4M | $51.1M | $53.4M | $51.5M | $48.4M |
| Sales, general & admin | $51.8M | $45.8M | $38.7M | $36.3M | $42.3M | $32.7M | $41.7M | $35.9M | $49.3M | $41.9M | $33.1M | $31.8M |
| Total operating expenses | $112.6M | $113.8M | $98.7M | $83.6M | $97.6M | $80.9M | $77.0M | $86.4M | $100.4M | $95.2M | $85.5M | $80.2M |
| Operating income | −$61.7M | −$69.8M | −$64.7M | −$55.6M | −$71.3M | −$64.4M | −$69.4M | −$80.3M | −$99.3M | −$95.2M | −$85.4M | −$80.1M |
| Interest income | $3.2M | $736,000 | $579,000 | $772,000 | $818,000 | $520,000 | $769,000 | $638,000 | $833,000 | $160,000 | $623,000 | $610,000 |
| Interest expense | $20,000 | $28.5M | $27.2M | $27.6M | $28.9M | $28.9M | $14.9M | $40.2M | $39.0M | $37.5M | $32.1M | $35.0M |
| Income before taxes | −$230.4M | −$632.8M | −$62.1M | −$67.3M | −$92.3M | −$129.9M | −$59.2M | −$85.8M | −$134.6M | −$134.1M | −$233.5M | −$95.6M |
| Income taxes | — | −$9,000 | −$135,000 | −$35,000 | $269,000 | −$234,000 | $17,000 | — | −$4.4M | −$21,000 | −$40,000 | −$4.6M |
| Net income | −$230.4M | −$632.8M | −$61.9M | −$67.3M | −$92.6M | −$129.6M | −$59.2M | −$85.7M | −$134.6M | −$134.1M | −$233.4M | −$95.6M |
| EBITDA | −$226.0M | −$599.9M | −$31.0M | −$35.8M | −$59.5M | −$97.2M | −$40.1M | −$41.1M | −$91.2M | −$97.6M | −$196.8M | −$56.1M |
| EPS (diluted) | −$0.08 | −$0.08 | −$0.06 | −$0.07 | −$0.10 | −$0.15 | −$0.08 | −$0.12 | −$0.20 | −$0.20 | −$0.38 | −$0.19 |
| Gross margin | 99.4% | 99.5% | 88.9% | 87.1% | 99.5% | 99.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −120.4% | −157.9% | −169.0% | −173.5% | −269.8% | −390.1% | −919.0% | −1,314.3% | −9,487.4% | −237,990.0% | −61,430.9% | −97,726.8% |
| Net margin | −449.6% | −1,431.4% | −161.8% | −209.8% | −350.3% | −784.9% | −783.4% | −1,404.0% | −12,852.3% | −335,272.5% | −167,907.9% | −116,563.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IBRX's financial statements (latest annual report filed February 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IBRX financial results
In fiscal year 2025 (ended December 31, 2025), ImmunityBio reported revenue of $113.3 million, up 668.3% from the year before. It had a net loss of $351.4 million, a net profit margin of −310.2%. Diluted earnings per share came to −$0.38. Over five years revenue grew at an average rate of 184.8% a year.
See the IBRX stock overview for the latest quote and news, or the IBRX chart for price history and technical indicators.
IBRX income statement FAQ
What is ImmunityBio's annual revenue?
ImmunityBio reported total revenue of $113.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 668.3% from $14.7 million the previous year.
Is ImmunityBio profitable?
No. ImmunityBio reported a net loss of $351.4 million in fiscal 2025, a net profit margin of −310.2%; its operating margin was −226.0%.
What is ImmunityBio's gross margin?
ImmunityBio's gross margin was 99.3% in fiscal 2025: for every $100 of revenue, ImmunityBio kept $99 after the direct cost of its products and services.
How much does ImmunityBio spend on research and development?
ImmunityBio spent $207.9 million on research and development in fiscal 2025, 183.5% of revenue.
How fast is ImmunityBio growing?
Revenue grew 184.8% a year on average over the last five fiscal years, from $0.6 million to $113.3 million.
What are ImmunityBio's earnings per share?
ImmunityBio earned $-0.38 per diluted share in fiscal 2025, compared with $-0.60 a year earlier.
When will ImmunityBio report its next earnings?
ImmunityBio is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens.
When does ImmunityBio's fiscal year end?
ImmunityBio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 23, 2026.